EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort Study

Frederikke Hjortdahl, Marianne Baastrup Soendergaard, Susanne Hansen, Anne-Sofie Bjerrum, Anna von Bülow, Ole Hilberg, Barbara Bonnesen, Claus Rikard Johnsen, Sofie Lock Johansson, Linda Makowska Rasmussen, Johannes Martin Schmid, Charlotte Suppli Ulrik und 3 weitere

Lung · 2025-12 · 203 (1)

DOI: 10.1007/s00408-025-00796-5 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Lung, online erschienen am 11.03.2025. Verfasst von Frederikke Hjortdahl und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Asthma, Budesonide, Adrenal Cortex Hormones, Biological Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Copenhagen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In severe asthma, intensive (“ supratherapeutic ”) doses of inhaled corticosteroids (ICS) are often used. The prevalence of supratherapeutic ICS use and its impact on corticosteroid-related comorbidities is poorly understood. We aimed to describe the prevalence of supratherapeutic ICS use in severe asthma, its relation to corticosteroid-related comorbidities, and changes in prescribed and redeemed ICS dose after 12 months of biologic therapy.

Methods

Patients from the nationwide Danish Severe Asthma Register (DSAR) receiving biologic therapy > 12 months were included. Supratherapeutic doses were defined as > 1600 µg budesonide daily. Baseline characteristics, comorbidity burden, and change in ICS use after 12 months of biologic therapy was stratified according to ICS use at baseline.

Results

We included 652 patients in our analyses and 156 (24%) were supratherapeutic ICS users prior to initiation of biologic therapy. Supratherapeutic ICS users had a higher baseline prevalence of cataracts at 14 vs 8.1%; p = 0.025. No differences in other corticosteroid-related comorbidities were observed. No change in prevalence of prescribed supratherapeutic ICS was seen after 12 months of biologic therapy. However, a reduction in ICS adherence among supratherapeutic users was observed with 72% of patients demonstrating > 80% adherence at 12 months, compared to 83% at baseline ( p < 0.001).

Conclusion

Supratherapeutic doses of ICS were used by almost one-fourth of the patients prior to initiation of biologic therapy and were associated with a higher prevalence of cataracts. Physician-driven ICS reduction was rare, yet supratherapeutic ICS users were found to self-regulate ICS therapy when treated with biologic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBudesonideAdrenal Cortex HormonesBiological TherapyAnti-Asthmatic AgentsHumansAdministration, InhalationMaleFemaleMiddle AgedDenmarkAdultRegistriesSeverity of Illness IndexAgedComorbidityTreatment Outcome

Stichwörter der Autor:innen

AdherenceComorbiditiesHigh doseOralProspective studyReductionSystemic

Substanzen

BudesonideAdrenal Cortex HormonesAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark.
  • Centre for Clinical Research and Prevention, Frederiksberg Hospital, Copenhagen, Denmark.
  • Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
  • Sygehus Lillebælt, Vejle Sygehus, Vejle, Denmark.
  • Department of Respiratory Medicine, Gentofte University Hospital, Hellerup, Denmark.
  • Allergy Clinic, Gentofte University Hospital, Hellerup, Denmark.

Förderung

  • Copenhagen University

Zitieren

APA

Hjortdahl, F., Soendergaard, M. B., Hansen, S., Bjerrum, A. S., von Bülow, A., Hilberg, O., Bonnesen, B., Johnsen, C. R., Johansson, S. L., Rasmussen, L. M., Schmid, J. M., Ulrik, C. S., Walls, A. B., Porsbjerg, C., & Håkansson, K. E. J. (2025). Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort Study. Lung, 203(1). https://doi.org/10.1007/s00408-025-00796-5

Vancouver

Hjortdahl F, Soendergaard MB, Hansen S, Bjerrum AS, von Bülow A, Hilberg O, et al. Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort Study. Lung. 2025;203(1). doi:10.1007/s00408-025-00796-5

BibTeX
@article{Hjortdahl2025,
  author = {Hjortdahl, Frederikke and Soendergaard, Marianne Baastrup and Hansen, Susanne and Bjerrum, Anne-Sofie and von Bülow, Anna and Hilberg, Ole and Bonnesen, Barbara and Johnsen, Claus Rikard and Johansson, Sofie Lock and Rasmussen, Linda Makowska and Schmid, Johannes Martin and Ulrik, Charlotte Suppli and Walls, Anne Byriel and Porsbjerg, Celeste and Håkansson, Kjell Erik Julius},
  title = {Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort Study},
  journal = {Lung},
  year = {2025},
  volume = {203},
  number = {1},
  doi = {10.1007/s00408-025-00796-5}
}
Kostenlos starten →